We provide you with 20 years of free, institutional-grade data for ADAP stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ADAP. Explore the full financial landscape of ADAP stock.
| Reported Date | CIK | Ticker | Type |
|---|
Adaptimmune Therapeutics plc(NASDAQ:ADAP) 
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to ide...
Website: http://www.adaptimmune.com
Full Time Employees: 420
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about ADAP stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.